Edition:
United States

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

75.25SEK
1 Dec 2016
Change (% chg)

1.00kr (+1.35%)
Prev Close
74.25kr
Open
75.50kr
Day's High
75.75kr
Day's Low
74.25kr
Volume
15,153
Avg. Vol
73,126
52-wk High
83.00kr
52-wk Low
46.90kr

MVIRb.ST

Chart for MVIRb.ST

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.30
Market Cap(Mil.): kr1,911.08
Shares Outstanding(Mil.): 26.36
Dividend: --
Yield (%): --

Financials

  MVIRb.ST Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -6.41 -- --
ROI: -12.33 -1.09 14.95
ROE: -12.51 -2.39 16.29

BRIEF-Medivir Q3 loss after tax 50.4 mln SEK

* Says net turnover totalled sek 67.8 million (111.5 m), of which sek 12.4 million (69.0 m) comprised royalties for simeprevir

Nov 10 2016

BRIEF-Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs

* Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs Source text for Eikon: Further company coverage:

Nov 02 2016

BRIEF-Tetralogic announces pacts to restructure convertible debt

* Tetralogic announces agreements to sell smac mimetic and hdac inhibitor assets to medivir and to restructure its convertible senior notes and delisting of common stock

Nov 02 2016

BRIEF-Medivir to focus exclusively on oncology, cuts cost by 110 mln SEK/year

* Medivir focuses exclusively on oncology and reorganizes to significantly reduce the cost structure

Oct 10 2016

BRIEF-Medivir: recommendation to go ahead in MIV-711 osteoarthritis trial

* MIV-711 osteoarthritis trial: recommendation to go ahead based on independent review of safety data, and first patient enrolled in extension study

Sep 23 2016

BRIEF-Medivir reports positive phase IIa data for simeprevir

* Interim results from phase IIa trial evaluating triple combination including simeprevir demonstrates high level of efficacy in HCV patients

Sep 09 2016

BRIEF-Medivir to split company before year-end

* Says proceeds with a separation of the company's operations

Aug 31 2016

BRIEF-Medivir licenses rights to MIV-802 to Trek Therapeutics

* Says Medivir is entitled to receive milestones based on successful clinical development and royalties capped at a mid-teens percentage upon commercialization of MIV-802 containing products

Aug 17 2016

BRIEF-Medivir swings to Q2 loss, sales fall

* Q2 net turnover totalled SEK 81.3 million (245.8 m), of which SEK 24.2 million (165.6 m) comprised royalties for simeprevir

Aug 17 2016

BRIEF-Medivir's new interim data to be presented at conference

* Medivir: new interim phase IIA data on simeprevir in combination with other DAAS will be presented at the upcoming EASL AASLD special conference Source text for Eikon: Further company coverage:

Aug 11 2016

Earnings vs. Estimates